Johnson & Johnson (NYSE:JNJ) Stock Holdings Cut by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Key Points

• Generali Investments Towarzystwo Funduszy Inwestycyjnych has reduced its stake in Johnson & Johnson by 38% to 4,850 shares, worth approximately $804,000, following a significant divestment of 2,970 shares in the first quarter.
• In contrast, GAMMA Investing LLC increased its holdings in Johnson & Johnson by over 24,000%, acquiring more than 7 million shares and reaching a total valuation of about $1.2 billion.
• Johnson & Johnson recently declared a quarterly dividend of $1.30, representing an annualized dividend of $5.20 and a dividend yield of 3.1%, with a payout ratio of 55.61%.

Generali Investments Towarzystwo Funduszy Inwestycyjnych cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 38.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,850 shares of the company's stock after selling 2,970 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych's holdings in Johnson & Johnson were worth $804,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Johnson & Johnson by 24,450.4% during the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Johnson & Johnson by 134.5% during the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Northern Trust Corp grew its position in shares of Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.6%

NYSE:JNJ opened at $167.33 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $402.99 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 2.13 and a beta of 0.41. The firm has a fifty day simple moving average of $157.46 and a two-hundred day simple moving average of $156.68. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the company earned $2.82 earnings per share. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.1%. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on JNJ shares. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Raymond James Financial dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Finally, Guggenheim reaffirmed a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.